HRT will not shorten lives, women told after new research published

Follow-up to alarming reports issued at turn of century says women on therapy do not die sooner than those on placebosWomen will be able to take hormone replacement pills without worrying that the therapy will shorten their lifespans, according to the longest follow-up yet of research that raised fears about the risks of a once-popular treatment.That earlier research was stopped early when unexpected harm was found to be caused by the use of hormone replacement therapy (HRT) – oestrogen alone or in combination with progestin, a synthetic hormone.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Menopause Medical research Health Cancer & wellbeing Society Science World news Source Type: news

Related Links:

Ever since a report by a U.S. study claimed in 2002 that it carried a significant risk of breast cancer and heart disease, most menopausal women remain scared of taking it.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionBreast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
BackgroundDuring menopause women experience vasomotor and psychosexual symptoms that cannot entirely be alleviated with hormone replacement therapy (HRT). Besides, HRT is contraindicated after breast cancer. ObjectivesTo review the evidence on the effectiveness of psychological interventions in reducing symptoms associated with menopause in natural or treatment‐induced menopausal women. Search strategyMedline/Pubmed, PsycINFO, EMBASE and AMED were searched until June 2017. Selection criteriaRandomised controlled trials (RCTs) concerning natural or treatment‐induced menopause, investigating mindfulness or (cognitive‐)...
Source: BJOG: An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: Systematic Review Source Type: research
Abstract BACKGROUND: During menopause women experience vasomotor and psychosexual symptoms that cannot entirely be alleviated with hormone replacement therapy (HRT). Besides, HRT is contraindicated after breast cancer. OBJECTIVES: To review the evidence on the effectiveness of psychological interventions in reducing symptoms associated with menopause in natural or treatment-induced menopausal women. SEARCH STRATEGY: Medline/Pubmed, PsycINFO, EMBASE and AMED were searched until June 2017. SELECTION CRITERIA: Randomised controlled trials (RCTs) concerning natural or treatment-induced menopause, invest...
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
BOSTON (CBS) — Scientists at Imperial College London have developed a new class of experimental drugs to treat menopausal hot flashes. In a clinical trial involving 37 women, the compound called MLE4901 reduced the number of hot flashes by almost three-quarters and significantly reduced the severity. The drug blocks a chemical in the brain called neurokinin B and in the study the drug also improved sleep and concentration during the 4-week study period. MLE4901 can affect liver function but two similar drugs which don’t have this side effect are being studied in larger patient trials including one in the U.S. t...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Dr. Mallika Marshall Menopause Women's Health Source Type: news
Conclusions: Decisions regarding the use of HT in women who undergo BSO after detection of a BRCA mutation must be individualized based on careful consideration of the risks and benefits. However, the risks of a subsequent cancer diagnosis appear small, particularly in regards to the benefits of treatment afforded by HT.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
More News: Cancer | Cancer & Oncology | Hormone Replacement Therapy | Hormones | Men | Menopause | Research | Science | Women